Biotech investment set to bounce back in 2023

While the economic future is still murky, easing interest rates and cooling inflation means that biotech companies could be primed for a bounce-back 2023, The Wall Street Journal reported Jan. 17.

Advertisement

The SPDR S&P Biotech ETF is already up 5.9 percent this year, and during the JPMorgan Healthcare Conference Jan. 9-12, AstraZeneca, Ipsen and Chiesi announced separate deals in the $1 billion range.

The HHS timeline for Medicare drug-price negotiations has eased investors’ fears, the Journal reported.

Merck CEO Robert Davis used the word “confident” more than 20 times in his presentation at the JPMorgan healthcare conference, setting the tone for how the biotech industry feels in 2023.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The hidden cost of lost clinical time and how leading health systems are responding

Friday, August 7
12:00 PM - 1:00 PM CDT

Presenters: Kassaundra McKnight-Young, Zebra TechnologiesGregory Carras, Zebra TechnologiesJennifer Gene, Levata

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.